Gemcitabine monotherapy in patients with heavily treated nasopharyngeal cancer: a case series
ConclusionOur findings suggest that GEM monotherapy is well tolerated and has potential as an active agent in Japanese patients with recurrent/metastatic NPC who have been heavily pretreated.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Nasopharyngeal Cancer | Toxicology